MedTrace Logo

Influence of Periodontal Treatment on Systemic Inflammatory Mediators

NCT01201746 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 317

Last updated 2016-10-14

No results posted yet for this study

Summary

Currently the research issue in establishing the role of periodontal disease (PD) in coronary heart disease (CHD) risk is to define the pathways that lead to cause-effect relationship between PD and CHD. There is no consensus on definition of a periodontal disease case or the threshold level that may give clear indication for this relationship. Periodontal therapy has been used in different studies with the hope that a change in periodontal disease status may modify the factors associated with CHD risk. Many of these studies, on role of periodontal therapy in the reduction of CHD associated risk-factors, were based on small study samples, and very few studies were randomized controlled trials. So a need for large prospective studies is warranted in literature.----------- A single-blind parallel-arm randomized controlled clinical trial was designed to observe the influence of periodontal treatment on serum inflammatory mediators of hsC-reactive protein, white blood cells and fibrinogen in CHD patients.

Hypothesis: Periodontal therapy in CHD patients, by reducing periodontal inflammation, may decrease the host systemic inflammatory burden associated with atherogenic processes.

Conditions

Interventions

PROCEDURE

Delayed treatment

Scaling, Root Planing and oral hygiene instruction

PROCEDURE

Periodontal therapy

Scaling, root planning and oral hygiene instructions

Sponsors & Collaborators

  • Higher Education Commission (Pakistan)

    collaborator OTHER

  • Sheikh Zayed Federal Postgraduate Medical Institute

    lead OTHER

Principal Investigators

  • Ayyaz A Khan, Ph.D. · Sheikh Zayed Federal Postgraduate Medical Institute

  • Syed Akhtar H Bokhari, MCPS · Sheikh Zayed Federal Postgraduate Medical Institute

  • Mohammad Azhar, MRCP · Punjab Institute of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
31 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-04-30
Completion
2009-05-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201746 on ClinicalTrials.gov